Advocates In Action

Share Your Story

We are all in this fight together. We need our voices to be heard. Lend your voice to National Brain Tumor Society and help increase the volume of awareness.

Submit Your Story  |   Read Stories

Head to The Hill

Our annual advocacy day brings hundreds of brain tumor advocates from across the country to the nation’s capital to educate congressional delegates on the critical issues facing our community. Join us and we’ll provide you will all of the tools you’ll need to be an effective advocate!

Learn more  |  Become an Advocate

From the Blog

  • January 14, 2021

    NBTS Brain Tumor Clinical Trials Report: Q4 2020

    It can be hard to keep track of new clinical trial opportunities opening across the United States, especially during the current public health crisis created by the coronavirus (COVID-19). However, there are many clinical trials still actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for […]

    The post Read More

  • January 7, 2021

    New Treatment Arms Opening for Patients in NBTS-Funded GBM AGILE Clinical Trial

    Yesterday, it was announced that the GBM AGILE adaptive clinical trial platform is opening two new treatment arms, with one evaluating Kintara Therapeutics’s chemotherapy, VAL-083, and Kazia Therapeutics’s targeted therapy, paxalisib.  “NBTS has long supported GBM AGILE as a scientifically cutting-edge and more patient-friendly way to develop and evaluate emerging new treatments for pati

    Read More

  • December 19, 2020

    4 Big Takeaways From the 2020 Annual Meeting of the Society for Neuro-Oncology

    A move to a virtual platform didn’t diminish the quality of the 2020 Annual Meeting of the Society for Neuro-Oncology (SNO), the yearly gathering of the world’s foremost brain tumor researchers and clinicians. As usual, the National Brain Tumor Society was a proud platinum sponsor of this important conference and deployed our own team of […]

    The post Read More

More from the blog